Skye Bioscience (SKYE) presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity Mouse Model” at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Key takeaways from the DIO studies: Nimacimab showed significant additive weight loss effects when combined with suboptimal or clinically active dose levels of tirzepatide. Nimacimab weight loss was durable after treatment discontinuation. Nimacimab treatment after tirzepatide discontinuation improved the weight rebound profile. Nimacimab weight loss was not primarily driven by caloric restriction. Nimacimab enhanced weight loss induced by semaglutide.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/14/26
- Skye Bioscience provides 2026 corporate outlook
- What Investors Can Learn from the Skye Bioscience Securities Fraud Allegations: A Risk Assessment Guide
- VTI ETF Daily Update — 1/7/26
- Skye Bioscience: ENHANZE Partnership Unlocks Nimacimab Dosing, De-Risks Phase 2b Path and Supports Buy Rating